MNPR

Monopar Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality1/10
  • Growth↓ 3/10
  • Value↑ 6/10
Monopar Therapeutics sales and earnings growth
MNPR Growth
Neutral
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 51.63%
  • FCF Y/Y↓ 3.84%
Monopar Therapeutics gross and profit margin trends
MNPR Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ 850.88%
Monopar Therapeutics net debt vs free cash flow
MNPR Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Monopar Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks